Consensus $2.52. The company said, “Baxter (BAX) now expects sales growth from continuing operations of 6% to 7% on a reported basis. On an operational basis, Baxter expects sales growth of 3% to 4%. The company now expects adjusted earnings from continuing operations, before special items, of $2.42 to $2.52 per diluted share. Baxter’s updated guidance attempts to capture potential downside risks associated with factors primarily impacting the company’s Medical Products & Therapies segment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: